Latest news with #Docosanol
Associated Press
10-04-2025
- Health
- Associated Press
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Ruvidar TM has been proven more effective in the treatment of Herpes Simplex Virus, Type 1 ('HSV-1") versus FDA-approved, standard of care treatments Acyclovir (5%) and Abreva (10% Docosanol) in a preclinical animal model. In the latest Theralase® research, Balb/C mice were infected with human HSV-1 virus on Day 0. TM (1%). To view an enhanced version of this graphic, please visit: Figure 2. Abreva (10% Docosanol) (6 days of treatment x 5 times per day) To view an enhanced version of this graphic, please visit: Figure 3. Ruvidar TM (1%) (5 days of treatment x once per day) To view an enhanced version of this graphic, please visit: The results support the safety and efficacy of topically applied non-light activated Ruvidar® for accelerated healing of cutaneous HSV-1 lesions in a mouse model. Pavel Kaspler, Ph.D., Research Scientist, Theralase®, who conducted the preclinical study stated, " I have now had the opportunity to conduct my next set of experiments, where I increased the number of daily applications of Acyclovir (5%) and Abreva (10% Docosanol) from once per day to 5 times daily for 5 and 6 days, respectively. In this set of experiments, Ruvidar TM (1%) remained at once daily for 5 days. As can be clearly seen from the photographs, Ruvidar TM was successfully able to completely heal the HSV-1 lesions in an animal model; whereas, neither Abreva (10% Docosanol) nor Acyclovir (5%) were able to completely heal them. A very interesting observation from this experiment is that Ruvidar TM (1%) was able to completely heal the HSV-1 lesions at a fraction of the dose of the other two FDA approved drugs and completed this task with an application frequency of only once per day versus 5 times daily. My next set of experiments, in conjunction with my colleagues, and Dr. Mandel will be to optimize the formulation that will be analyzed in GLP toxicology, as well as clinically evaluated in a Phase I, II and III clinical study.' Arkady Mandel, M.D., Ph.D., Chief Scientific Officer, Theralase® stated, " The preclinical data is what I would have predicted based on my previous research into this versatile drug; Ruvidar TM (1%) is superior in efficacy, when directly compared to two FDA-approved drugs; specifically: Acyclovir (5%) and Abreva (10% Docosanol). As one of the potential Mechanisms Of Action ('MOA'), it is well established in the literature that the glycoproteins of the HSV-1 virus (glycans—gB and gC) are negatively charged, as is the Heparan Sulphate ('HS') receptors on a cell's surface (preferred binding site of the virus on a cell). This provides a novel mechanism (based on controlled electrostatic repulsion) that addresses how viruses balance between optimized viral attachment to target cells and efficient egress of progeny virus. 3,4 On the other hand, Ruvidar TM is positively charged. 5 This allows Ruvidar TM the unique ability to be able to bind to and block the glycoproteins on HSV-1, preventing binding to host cells, as well as on the HS cell surface receptors preventing the efficient egress of progeny virus. This leads to an inability of the virus to replicate, allowing accelerated healing of cold sore lesions. The Theralase® research team is currently investigating additional MOAs to explain the ability of Ruvidar TM to effectively inactivate HSV-1 and to stop the progression of cold sore lesions in their tracks. ' Roger DuMoulin-White, President and Chief Executive Officer, Theralase® stated, " I am delighted with the research team's latest set of experiments demonstrating the superiority of Ruvidar TM in the effective destruction of HSV-1 lesions versus Acyclovir (5%) and Abreva (10% Docosanol). Based on the success of this latest preclinical research, Theralase® will commence formulation of Ruvidar TM into topical form, complete GLP toxicology and commence a Phase I/II adaptive clinical study to demonstrate the safety and efficacy of Ruvidar TM in the accelerated healing of cold sore lesions in humans. ' About Herpes Simplex: Herpes Simplex Virus ('HSV'), known as herpes, is a very common infection that can cause painful blisters or ulcers on the skin of an individual. It primarily spreads by skin-to-skin contact, while it is treatable, it is not curable. 1 There are two main types of HSV: 1 Type 1 ('HSV-1") generally spreads by oral contact and causes infections in or around the mouth, vermilion, upper or lower lip region (oral herpes or cold sores). It can also cause genital herpes. A majority of adults are infected with HSV-1. Type 2 ('HSV-2") spreads by sexual contact and causes herpes in the genital region of an individual. An estimated 3.8 billion people under the age of 50 (64%) globally have HSV-1, the main cause of oral herpes. An estimated 520 million people aged 15 to 49 (13%) globally have HSV-2, the main cause of genital herpes. 1 The global HSV treatment market size was estimated at $USD 2.8 billion in 2024 and is expected to balloon to $USD 4.7 billion by 2033. 2 References: 1 Herpes simplex virus 2 3 Transforms of Cell Surface Glycoproteins Charge Influences Tumor Cell Metastasis via Atypically Inhibiting Epithelial-Mesenchymal Transition Including Matrix Metalloproteinases and Cell Junctions. Mingzhe Wang et al. Bioconjugate Chemistry. Vol. 34. Issue 8. July 2023 4 Olofsson S, Bally M, Trybala E, Bergström T. Structure and Role of O-Linked Glycans in Viral Envelope Proteins. Annu Rev Virol. 2023 Sep 29;10(1):283-304. doi: 10.1146/annurev-virology-111821-121007. Epub 2023 Jul 6. PMID: 37285578. 5 Ruvidar (TM) Enhances Efficacy of Cancer Drug About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
Yahoo
10-04-2025
- Health
- Yahoo
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that RuvidarTM has been proven more effective in the treatment of Herpes Simplex Virus, Type 1 ("HSV-1") versus FDA-approved, standard of care treatments Acyclovir (5%) and Abreva (10% Docosanol) in a preclinical animal model. In the latest Theralase® research, Balb/C mice were infected with human HSV-1 virus on Day 0. On Day 1 post-infection, these mice were treated with either: Acyclovir (5%), Abreva (10% Docosanol) or RuvidarTM (1%). Figure 1. Acyclovir (5%) (5 days of treatment x 5 times per day)To view an enhanced version of this graphic, please visit: Figure 2. Abreva (10% Docosanol) (6 days of treatment x 5 times per day)To view an enhanced version of this graphic, please visit: Figure 3. RuvidarTM (1%) (5 days of treatment x once per day)To view an enhanced version of this graphic, please visit: The results support the safety and efficacy of topically applied non-light activated Ruvidar® for accelerated healing of cutaneous HSV-1 lesions in a mouse model. Pavel Kaspler, Ph.D., Research Scientist, Theralase®, who conducted the preclinical study stated, "I have now had the opportunity to conduct my next set of experiments, where I increased the number of daily applications of Acyclovir (5%) and Abreva (10% Docosanol) from once per day to 5 times daily for 5 and 6 days, respectively. In this set of experiments, RuvidarTM (1%) remained at once daily for 5 days. As can be clearly seen from the photographs, RuvidarTM was successfully able to completely heal the HSV-1 lesions in an animal model; whereas, neither Abreva (10% Docosanol) nor Acyclovir (5%) were able to completely heal them. A very interesting observation from this experiment is that RuvidarTM (1%) was able to completely heal the HSV-1 lesions at a fraction of the dose of the other two FDA approved drugs and completed this task with an application frequency of only once per day versus 5 times daily. My next set of experiments, in conjunction with my colleagues, and Dr. Mandel will be to optimize the formulation that will be analyzed in GLP toxicology, as well as clinically evaluated in a Phase I, II and III clinical study." Arkady Mandel, M.D., Ph.D., Chief Scientific Officer, Theralase® stated, "The preclinical data is what I would have predicted based on my previous research into this versatile drug; RuvidarTM (1%) is superior in efficacy, when directly compared to two FDA-approved drugs; specifically: Acyclovir (5%) and Abreva (10% Docosanol). As one of the potential Mechanisms Of Action ("MOA"), it is well established in the literature that the glycoproteins of the HSV-1 virus (glycans—gB and gC) are negatively charged, as is the Heparan Sulphate ("HS") receptors on a cell's surface (preferred binding site of the virus on a cell). This provides a novel mechanism (based on controlled electrostatic repulsion) that addresses how viruses balance between optimized viral attachment to target cells and efficient egress of progeny virus.3,4 On the other hand, RuvidarTM is positively charged.5 This allows RuvidarTM the unique ability to be able to bind to and block the glycoproteins on HSV-1, preventing binding to host cells, as well as on the HS cell surface receptors preventing the efficient egress of progeny virus. This leads to an inability of the virus to replicate, allowing accelerated healing of cold sore lesions. The Theralase® research team is currently investigating additional MOAs to explain the ability of RuvidarTM to effectively inactivate HSV-1 and to stop the progression of cold sore lesions in their tracks." Roger DuMoulin-White, President and Chief Executive Officer, Theralase® stated, "I am delighted with the research team's latest set of experiments demonstrating the superiority of RuvidarTM in the effective destruction of HSV-1 lesions versus Acyclovir (5%) and Abreva (10% Docosanol). Based on the success of this latest preclinical research, Theralase® will commence formulation of RuvidarTM into topical form, complete GLP toxicology and commence a Phase I/II adaptive clinical study to demonstrate the safety and efficacy of RuvidarTM in the accelerated healing of cold sore lesions in humans." About Herpes Simplex:Herpes Simplex Virus ("HSV"), known as herpes, is a very common infection that can cause painful blisters or ulcers on the skin of an individual. It primarily spreads by skin-to-skin contact, while it is treatable, it is not curable.1 There are two main types of HSV:1 Type 1 ("HSV-1") generally spreads by oral contact and causes infections in or around the mouth, vermilion, upper or lower lip region (oral herpes or cold sores). It can also cause genital herpes. A majority of adults are infected with HSV-1. Type 2 ("HSV-2") spreads by sexual contact and causes herpes in the genital region of an individual. An estimated 3.8 billion people under the age of 50 (64%) globally have HSV-1, the main cause of oral herpes. An estimated 520 million people aged 15 to 49 (13%) globally have HSV-2, the main cause of genital herpes.1 The global HSV treatment market size was estimated at $USD 2.8 billion in 2024 and is expected to balloon to $USD 4.7 billion by 2033.2 References:1 Herpes simplex virus2 Herpes Simplex Virus Treatment Market Size, Top Share, Key Developments | By 20333 Transforms of Cell Surface Glycoproteins Charge Influences Tumor Cell Metastasis via Atypically Inhibiting Epithelial-Mesenchymal Transition Including Matrix Metalloproteinases and Cell Junctions. Mingzhe Wang et al. Bioconjugate Chemistry. Vol. 34. Issue 8. July 20234 Olofsson S, Bally M, Trybala E, Bergström T. Structure and Role of O-Linked Glycans in Viral Envelope Proteins. Annu Rev Virol. 2023 Sep 29;10(1):283-304. doi: 10.1146/annurev-virology-111821-121007. Epub 2023 Jul 6. PMID: 37285578.5 Ruvidar(TM) Enhances Efficacy of Cancer Drug About Theralase® Technologies Inc.:Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements:This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPAChief Financial Officer X 224khachey@ To view the source version of this press release, please visit Sign in to access your portfolio
NBC News
18-02-2025
- Health
- NBC News
The best products for cold sores, according to dermatologists
Like acne, a cold sore outbreak can be a frustrating dilemma that makes everyday activities (like eating, drinking and talking) cumbersome. Thankfully, the best products can help eliminate some pain and discomfort associated with the condition. 'Depending on how often you have cold sores outbreaks, the most effective treatment would be with an oral medication that can be prescribed by a physician, to be used either for flares (if you get them rarely), or on a daily basis to prevent outbreaks (if you get flares frequently),' says Dr. David Li, a board-certified dermatologist based in Massachusetts. 'Topical treatments can be found over the counter as well.' We spoke with two board-certified dermatologists about the best topical treatments and how to know which one is right for you. We also put together a list of what to shop based on their recommendations and guidance. How we picked the best products for cold sores The best products for cold sores should reduce pain, discomfort and redness as well as help minimize the spread, according to our experts. Below, we highlight their suggestions about what to consider when curating this list: Type: You can find cold sore treatments in patch, gel and cream form. Patches act as a physical barrier for the cold sore, helping to reduce the spread of the virus, says Li. They also prevent exposure to potential irritants, offer a discreet way of covering up the sore and are a good way to prevent picking or touching it. Gels provide a protective barrier due to their thicker consistency, and some formulas dry into a film, which can shield the cold sore from bacteria, dirt and further irritation. If you're seeking a more lightweight formula with quicker absorption and the ability to layer makeup on top, a cream may be a good option. Active ingredients: When shopping for the best products for cold sores, there are a few active ingredients to be aware of. Docosanol is an over-the-counter antiviral that helps prevent the virus from spreading. Rather than attacking the virus directly, it blocks the virus from reaching healthy cells, thus slowing the spread, reducing the severity of the cold sore outbreak and shortening healing time. Hydrocortisone is another ingredient that can help offer cold sore relief. This mild corticosteroid helps minimize inflammation, redness and swelling associated with the outbreak, and is a good ingredient to use in conjunction with oral medication. Finally, hydrocolloid, often found in patches, creates a moist environment for the cold sore to prevent it from drying out. The best products for cold sores in 2025 Dr. Tracy Evans, a board-certified dermatologist and medical director of Pacific Skin and Cosmetic Dermatology, points to this formula from Abreva as one of the best topical treatments for cold sores because it 'penetrates deeply into the skin to block the herpes virus from entering healthy cells.' It's formulated with 10% docosanol, an ingredient that Li says has been studied to reduce healing time by 18 hours. The cream also comes in small, portable packaging that makes it easy to travel with or take on the go. For an anti-inflammatory treatment that can help calm cold sores and reduce redness, itching and pain, Evans recommends this hydrocortisone cream. In addition to 1% hydrocortisone, this has vitamins A, C and E in it to keep skin nourished, according to the brand. Plus, you can use it to offer relief for other skin conditions such as eczema, allergic reactions and dermatitis. To use, Evans says to apply a half pea-sized amount three times a day. Evans is a fan of these patches from Hero Cosmetics because they're discreet with a thin profile and matte finish — plus, they help promote healing. While designed primarily for acne, they're made with medical-grade hydrocolloid, which absorbs fluids and keeps the cold sore from drying out. Choose from a 72-count or 24-count package. This cold sore treatment is ideal if you're dealing with high levels of discomfort because it's made with camphor and phenol to provide a numbing effect that temporarily halts the pain, according to the brand. It also has aloe, which helps soothe skin and prevent dryness and cracking from exacerbating any tenderness. Both adults and children over two can use the formula, and it has a precise applicator that disperses a small amount of product to ensure there's no waste. If your cold sore has entered the crust-over stage, this noncomedogenic facial cleanser is a good choice. It's gentle, won't contribute to further irritation and supports healing since it doesn't have any harsh acids or alcohols. Instead, it's made with ceramides, which Li says are helpful to protect the skin's barrier, in addition to trapping moisture within the surface of the skin. 'This has the benefit of preventing moisture loss in addition to protecting the barrier from harsh compounds in the environment,' he says. Application-wise, the pump makes for sanitary and mess-free usage. Mederma Healing Patch The benefits of this patch from Mederma is two-fold: It makes your cold sore appear less visible, and it has hydrocolloid gel technology to speed up healing, says Evans. This comes with 15 patches in an easily transportable box. It also seamlessly fits into your routine, as you can also apply lipstick and makeup on top. How to shop for cold sore treatments When shopping, our experts recommend looking at several factors, including the form of treatment. What your symptoms are will impact what kind of treatment you'll need: To speed up healing, look for antiviral treatments with docosanol or lysine. For easing itching, burning and pain, look for numbing agents, often found in gels. Gels typically consist of one or more active ingredients that dull the pain of the HSV infection using benzocaine, lidocaine or menthol, says Li. To support recovery, look for protective products like patches. Formulas with aloe, honey and vitamin E can also help with skin repair and protection. Meet our experts At NBC Select, we work with experts who have specialized knowledge and authority based on relevant training and/or experience. We also take steps to ensure all expert advice and recommendations are made independently and without undisclosed financial conflicts of interest. Why trust NBC Select? Michelle Rostamian has more than 10 years of experience covering beauty and skin care topics. For this story, Rostamian spoke to board-certified dermatologists about the causes and treatments for cold sores, and included their direct recommendations and products based on their guidance.
